Every 10-Q that CONMED Corporation (CNMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CNMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNMD filings page.
CONMED Corporation reported Q2 2026 net sales of $343.5 million, roughly flat year over year, while net income rose to $23.1 million and diluted EPS to $0.77. For the first six months, net sales were $660.5 million and net income $36.9 million, or $1.22 per diluted share.
Gross margin expanded to 57.5% in Q2 and 57.7% year to date, helped by an $8.5 million IEEPA tariff refund and favorable mix, partly offset by a $6.9 million charge to write down inventory, equipment and tooling for discontinued products. Selling and administrative expense rose to 42.4% of sales in Q2, reflecting a $4.4 million loss and $9.8 million goodwill write-off on the sale of a gastroenterology business, higher consulting and optimization costs, and advisory compensation, partially offset by prior‑year CEO advisory costs and gains on earlier gastro asset sales. R&D increased to 4.5% of sales in Q2, including European Union Medical Device Regulation compliance spending.
Orthopedic surgery sales grew 8.2% in Q2 on powered instruments, sports medicine, visualization and BioBrace, while general surgery declined as gastroenterology sales fell to $4.7 million from $25.3 million. Total debt was $834.2 million, including a new $450.0 million Term A‑2 loan and $193.0 million drawn on the revolver. The company repurchased $645.2 million principal of its 2.250% Notes for $637.2 million, recording an $8.1 million extinguishment gain, and ended the quarter with $37.3 million in cash and $455.5 million of revolver availability, stating that existing resources are expected to cover needs for at least 12 months.
CONMED Corporation reported higher profitability for the quarter ended March 31, 2026, despite slightly lower sales. Net sales were $317.0 million versus $321.3 million a year earlier, mainly because gastroenterology product revenue fell to $9.5 million from $25.0 million as the company exited that portfolio.
Net income more than doubled to $13.8 million from $6.0 million, and diluted EPS rose to $0.45 from $0.19, helped by stronger gross margins and lower selling and administrative costs. Gross margin expanded to 57.9% from 55.3%, aided by a benefit from terminating the Gore VIABIL biliary stent distribution agreement and lower supply-chain consulting costs. Operating cash flow declined to $13.5 million from $41.5 million, reflecting working-capital swings and higher incentive payments. The company generated $7.0 million from selling certain gastroenterology assets, repurchased $37.0 million of stock, and ended the quarter with $35.0 million in cash and $860.9 million of total debt, including $800.0 million of 2.250% convertible notes due 2027 that it plans to refinance.
CONMED (CNMD) reported Q3 2025 results. Net sales were $337.9 million, up 6.7% year over year, led by General Surgery and Orthopedic Surgery. Diluted EPS was $0.09 as net income fell to $2.9 million.
Gross margin declined to 49.2% (down 730 bps). The quarter included $19.7 million of write-offs tied to canceled product lines and discontinued SKUs, $3.7 million of consulting costs in cost of sales, and tariff impacts. Selling and administrative expense rose to $140.3 million, reflecting $5.5 million in operational optimization consulting, expense from contingent consideration fair value changes, and advisory services earlier in the year.
Year to date, operating cash flow was $124.4 million. Cash was $38.9 million and total long‑term debt was $853.0 million, including $60.0 million outstanding under the term loan and $800.0 million of 2.250% convertible notes due 2027. Interest expense decreased to $7.6 million. The company noted DOJ closed its voluntary disclosure matter with no action.